STOCKHOLM, June 4, 2019 /PRNewswire/ -- Medivir AB
(Nasdaq Stockholm: MVIR) announces that the company will
participate at the 2019 BIO International Convention in
Philadelphia, US. The presentation
will take place at 11.30am local time
on Wednesday, June 5, 2019.
Christina Herder, EVP Strategic
Business Development, will present the developments in the
company's project portfolio.
The presentation will be available via Medivirs website;
www.medivir.com.
For further information, please contact:
Uli Hacksell, CEO
Medivir AB
mobile: +46(0)73-125-0615.
About Medivir
Medivir develops innovative drugs with a focus on cancer where
the unmet medical needs are high. The company is investing in
indication areas where available therapies are limited or missing
and there are great opportunities to offer significant improvements
to patients. Collaborations and partnerships are important parts of
Medivir's business model and the drug development as well as the
commercialization is conducted either by Medivir or in partnership.
Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's
Small Cap list. www.medivir.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/medivir/r/medivir-to-present-at-the-2019-bio-international-convention,c2833318
The following files are available for download:
|
https://mb.cision.com/Main/652/2833318/1057278.pdf
|
Press release
(PDF)
|
View original
content:http://www.prnewswire.com/news-releases/medivir-to-present-at-the-2019-bio-international-convention-300861340.html
SOURCE Medivir
